Waverley Pharma Inc.
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
810,000
P/E Ratio
-
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.
Healthcare
Biotechnology
TSXV
Key Financial Metrics
475,373
Revenue
-947,077
Net Income
C$-0.02
EPS (Diluted)
-410,192
Free Cash Flow
Profitability
Gross Margin
45.0%
Operating Margin
-156.4%
Net Profit Margin
-199.2%
EBITDA
-656,129
Returns & Efficiency
Return on Assets (ROA)
-46.3%
Return on Equity (ROE)
-
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
2.0M
Total Debt
3.1M
Debt to Equity
-
Current Ratio
0.19
Company Info
| Industry | Biotechnology |
| HQ | Winnipeg, Canada |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | www.waverleypharma.com |
Peers
Bausch + Lomb Corporation
BLCO.TO
7.9B
P/E: --
Bausch Health Companies Inc.
BHC.TO
2.5B
P/E: 12.0
Extendicare Inc.
EXE.TO
2.5B
P/E: 23.7
Sienna Senior Living Inc.
SIA.TO
2.2B
P/E: 53.2
Cronos Group Inc.
CRON.TO
1.4B
P/E: 24.1
Tilray Brands, Inc.
TLRY.TO
1.2B
P/E: --
WELL Health Technologies Corp.
WELL.TO
1.1B
P/E: --
Knight Therapeutics Inc.
GUD.TO
631.8M
P/E: --
Insider Activity
Sentiment
Neutral
Shares Bought
0
Shares Sold
0
Total Transactions
1
SEDAR+ Filings
View All Filings8
Annual Reports
26
Quarterly Reports
34
MD&A
27
News Releases
4
Material Changes
18
Governance
68
Certifications
50
Other
●
2018-07-30
●
2017-10-25
●
2017-09-20
●
2017-09-18
Interactive Charts
Company Profile
General Information
| Company Name | Waverley Pharma Inc. |
| Ticker | WAVE.V |
| Exchange | TSXV |
| Sector | Healthcare |
| Industry | Biotechnology |
| Headquarters | Winnipeg, Canada |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | www.waverleypharma.com |
Financial Summary
| Market Cap | 810,000 |
| Revenue | 475,373 |
| Net Income | -947,077 |
| P/E Ratio | N/A |
| EPS (Diluted) | C$-0.02 |
| Net Margin | -199.2% |
| ROE | N/A |
| Dividend Yield | N/A |
Business Description
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.